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Gene finding is a finite exercise, and a means to an end,
rather than an end in itself. The field of human genetics
should increasingly shift its attention from disease gene
identification to following through on next steps, most
importantly pursuing the biological mechanisms
underlying genotype-phenotype associations.From genetics to variant interpretation and
High-yield paradigms
We are in a period of rich discovery in human genetics
and genomics. The ascertainment of genetic variation,
previously the rate-limiting step for genetic analysis, has
been revolutionized by new technologies for high-density
genotyping, exome sequencing and genome sequencing.
Several high-yield paradigms - approaches that are ex-
ceptionally successful in generating discoveries - have
emerged that exploit these technologies to uncover the
genetic underpinnings of disease. For example, genome-
wide association studies (GWAS), typically involving
high-density genotyping in large case–control cohorts
(effectively genome-wide scans because of linkage dis-
equilibrium amongst common variants), have yielded
thousands of reproducible genotype-phenotype associa-
tions [1]. Exome sequencing, by enabling the identifica-
tion of highly penetrant rare variants and de novo
mutations, is driving a renaissance in monogenic dis-
ease gene discovery, adding hundreds of new discoveries
to the catalog of Mendelian disease genes [2]. Although
most studies that have used exome sequencing to assess
the contribution of rare variants to common diseases have
been underpowered, a bright spot is the genetics of neuro-
psychiatric diseases, such as autism and intellectual dis-
ability, in which an excess of severe de novo mutations in
probands highlights a clear path for pinpointing disease
genes despite the extreme genetic heterogeneity of these
phenotypes [3]. Analogous successes are taking place in
cancer genetics, a field in which hundreds of genes are be-
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sequencing [4]. The distinctions between these high-yield
paradigms are decreasing, as affordable whole-genome se-
quencing provides a comprehensive means for assessing
the contribution of de novo, rare and common variations
in both coding and non-coding regions of the genome to
the full spectrum of human phenotypes.disease mechanism
Amid this success, it is important to remember that genet-
ics is a means to one or several ends (such as a biological
understanding of disease mechanisms, or identifying the
basis of disease in a specific patient) rather than an end in
itself. The ultimate impact of our field will depend not
only on whether we can get the genetics right, but also on
whether or not subsequent goals are achieved. At the
same time, there are limits to what we can learn through
genetic analysis alone. Following up on the fruits of hu-
man genetics will increasingly require that we experimen-
tally characterize the variants and/or genes believed to
underlie human phenotypes. There are at least four con-
texts in which this exhortation is relevant.
First, the linkage disequilibrium that underlies the effi-
ciency of GWAS ironically limits their resolution. Al-
though GWAS have been very successful in identifying
reproducible ‘haplotype-phenotype’ associations (that is,
multiple common variants in linkage disequilibrium with
one another, all associated with the phenotype), the
number of association signals for which the causal com-
mon variant(s) and/or genes are definitively known is
disappointingly small. To the extent that the goal of
GWAS is to identify dysregulated or dysfunctional genes
(as opposed to loci) in common disease, GWAS are
analogous to a compendium of promising but undeni-
ably incomplete sentences. There are a few studies in
which extensive experimental follow-up has identified
the specific functional variants underlying an association,
but these are few and far between, and the challenge of
closing the gap between the number of genome-wide as-
sociations that are convincing and the number that are
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that require follow-up, we should be focused on defining
generically applicable functional assays or workflows for
chasing down causal variants within implicated haplo-
types [5]. This may be facilitated by the fact that most
causal variants underlying significant associations with
common diseases are likely to be regulatory. For example,
with the CRISPR/Cas9 system, it is possible to imagine
systematically introducing candidate causal variants for a
given association into a uniform genetic background in a
relevant cell type and then measuring their impact (alone
and in combination) on the transcriptional output of
nearby genes. A separate challenge is that functional as-
says do not easily lend themselves to the consistent statis-
tical standards that have been a mainstay of GWAS [6].
Therefore, an important question for the future is whether
standards of experimental evidence for implicating specific
variants or genes as ‘causal’ for associations can be defined
and consistently applied.
Second, although we have been quite successful in
identifying specific disease-associated genes in two do-
mains - Mendelian disease (germline mutations) and
cancer (somatic mutations) - we remain poorly equipped
to interpret sequence variants that are observed in indi-
vidual patients, that is, variants of uncertain significance
(VUS). The underlying problem is unlikely to be solved by
more sequencing: for example, the breast-cancer-associated
genes BRCA1 and BRCA2 have been sequenced in over a
million patients and yet a high proportion of returned re-
sults continue to be VUS. If anything, the challenge
posed by VUS is likely to profoundly deepen as the clin-
ical sequencing of human genomes accelerates and as
the list of genes for which sequencing is clinically mean-
ingful grows. In this context, functional assays may well
be the way forward.
The functional assessment of clinically observed variants
is nothing new. However, this has generally been retro-
spective: for instance, the functional characterization of
alleles that have already been observed in one or more pa-
tients. The recent emergence of massively parallel ap-
proaches for dense mutagenesis and the functional
analysis of specific sequences [7] may enable a different
paradigm, in which all possible variants of a clinically
relevant gene are functionally tested in advance of ever
having been observed in a patient. Provided that the re-
sults of the functional assay correlate with clinical con-
sequences, such ‘pre-computed’ interpretations could
then be used in the very first instance in which the vari-
ant was observed in the clinic, thereby eliminating or
minimizing VUS reports in that gene.
Third, the functional characterization of variants ob-
served in patients can prove useful for the implication of a
gene or locus in disease. However, it is important to be
cautious about how such data are used and interpreted [6].For example, it is often the case that a variant or muta-
tion will highlight a reasonable candidate gene, but no
‘second family’ is available, motivating experimental
characterization of the allele and/or gene to provide
supporting evidence. But given the ‘narrative potential’
[8] of any given gene, as well as the non-trivial probabil-
ity that a candidate mutation will be functional at the
molecular level but not causal for the phenotype being
investigated, the bar must be set extremely high for de-
claring success. It is far preferable that genes are impli-
cated on the basis of genetic analysis alone, or that
experimental information be used in a statistically rigor-
ous fashion to boost discovery power in the first place;
for example, to stratify genes [9] or variants [10] into
subsets in which the strength of association correlates
with molecular functionality.
Fourth, although genomics provides a systematic,
genome-wide means of identifying a gene or genes in
which variation contributes to the pathophysiology of a
given disease, understanding the role of these gene(s) in-
evitably requires experiments. This is ostensibly a task
for biologists rather than geneticists; however, geneticists
bear some degree of responsibility for ensuring that the
story does not end with genetics and, as such, there should
be no barriers against geneticists delving deeply into the
biology of gene mechanisms. Furthermore, the number of
genes implicated by genetic approaches in human pheno-
types but whose biological function remains poorly under-
stood is easily in the thousands. The armamentarium of
genomic approaches for observational (for example, tran-
scriptional profiling) and perturbational (for example,
genome-wide knockdown or knockout screens) experi-
ments may represent useful approaches for advancing our
fundamental understanding of the biological role(s) of im-
plicated genes in a scalable fashion.
In summary, to shed further light on the plethora of
established gene discoveries and locus associations, the
onus is on geneticists to take the next steps. A strength
of forward genetic approaches for gene finding has been
that they are systematic or ‘hypothesis free’; that is, all
genes are a priori equally likely candidates at the outset of a
study. This principle has served our field enormously well,
as it provides the freedom to make discoveries in expected
corners [11]. Although particular genes and variants will of
course require systems of experimental analysis that are
specific to the contexts and manner in which they function,
it may nonetheless prove powerful to carry this general
philosophy forward where possible; for example, genome-
wide screens for genetic or physical interactions, building
distributions of variant effect sizes, and so on.
A foundational goal of human genetics may be to un-
ravel the genetic basis of human disease, but the ultimate
impact of our field will be measured by whether and how
this knowledge is put to use. Furthermore, gene finding is
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http://genomemedicine.com/content/6/10/86a finite exercise, or at least subject to the law of diminish-
ing returns. Although the day when the apples get too
high to reach may still be in the future, we should not lose
sight of the fact that the ground is already littered with
apples. We must get going on carrying these discoveries
forward, lest we get buried in our own success.
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